


Searching News Database: ovarian cancers
HSMN NewsFeed - 13 Jan 2020
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
HSMN NewsFeed - 26 Nov 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
HSMN NewsFeed - 19 Nov 2019
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
HSMN NewsFeed - 26 Jan 2016
Abcodia Announces Expanded U.S. Availability of the ROCA(R) Test for Early Ovarian Cancer Detection
Abcodia Announces Expanded U.S. Availability of the ROCA(R) Test for Early Ovarian Cancer Detection
HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
HSMN NewsFeed - 13 Mar 2013
Vermillion Appoints Thomas McLain as President and Chief Executive Officer
Vermillion Appoints Thomas McLain as President and Chief Executive Officer
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 15 Jun 2011
Endocyte Names Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs
Endocyte Names Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs
HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
HSMN NewsFeed - 29 Oct 2007
European Symposium Focuses on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
European Symposium Focuses on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
HSMN NewsFeed - 29 Oct 2007
ChemGenex Announces Strategic Restructuring of Company to Focus on Late-Stage Cancer Portfolio
ChemGenex Announces Strategic Restructuring of Company to Focus on Late-Stage Cancer Portfolio
HSMN NewsFeed - 22 Oct 2007
European Symposium on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
European Symposium on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
HSMN NewsFeed - 4 Jul 2007
Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics
Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics
HSMN NewsFeed - 19 Jun 2007
OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
HSMN NewsFeed - 3 Jun 2007
Next Generation of Investigational Anti-Cancer Agents Unveiled at ASCO by AstraZeneca
Next Generation of Investigational Anti-Cancer Agents Unveiled at ASCO by AstraZeneca
HSMN NewsFeed - 25 Apr 2007
Thallion Pharmaceuticals Inc. Hires Executive Vice-President, Licensing and Development
Thallion Pharmaceuticals Inc. Hires Executive Vice-President, Licensing and Development
HSMN NewsFeed - 14 Nov 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
HSMN NewsFeed - 1 Nov 2006
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
HSMN NewsFeed - 1 Jun 2006
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Additional items found! 60
Members Archive contains
60 additional stories matching:
ovarian cancers
(Password required)
ovarian cancers
(Password required)
